Moran, Andrew <br/><br/>
Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?  [electronic resource] 

 -  Nature clinical practice. Cardiovascular medicine  Oct 2008 
 - 606-7 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1743-4300 
<br/><br/><label>Standard No.: </label>10.1038/ncpcardio1309  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenergic beta-Antagonists--economics<br/>Aged<br/>Angiotensin II Type 1 Receptor Blockers--economics<br/>Angiotensin-Converting Enzyme Inhibitors--economics<br/>Aspirin--economics<br/>Cardiovascular Agents--economics<br/>Computer Simulation<br/>Cost Savings<br/>Cost-Benefit Analysis<br/>Drug Costs<br/>Drug Therapy, Combination<br/>Humans<br/>Hypolipidemic Agents--economics<br/>Insurance, Pharmaceutical Services--economics<br/>Medicare--economics<br/>Models, Economic<br/>Myocardial Infarction--drug therapy<br/>Patient Compliance<br/>Quality-Adjusted Life Years<br/>Treatment Outcome<br/>United States